Intervention not reported
Debridement + antiviral (B) versus antiviral (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14 days
1 finding from 1 review
no estimate extracted
7 participants
Moderate
Intervention not reported
Vidarabine (B) versus inactive control (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14 days
1 finding from 1 review
no estimate extracted
7 participants
Low
Intervention not reported
Vidarabine (B) versus idoxuridine (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14 days
1 finding from 1 review
no estimate extracted
7 participants
Moderate
Intervention not reported
Trifluridine (B) versus idoxuridine (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14 days
1 finding from 1 review
no estimate extracted
7 participants
Moderate
Intervention not reported
Acyclovir (B) versus idoxuridine (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14 days
1 finding from 1 review
no estimate extracted
7 participants
Moderate
Intervention not reported
Brivudine (B) versus idoxuridine (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14 days
1 finding from 1 review
no estimate extracted
7 participants
Moderate
Intervention not reported
Trifluridine (B) versus vidarabine (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14 days
1 finding from 1 review
no estimate extracted
7 participants
Moderate
Intervention not reported
Acyclovir (B) versus vidarabine (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14 days
1 finding from 1 review
no estimate extracted
7 participants
Moderate
Live birth or ongoing pregnancy · women undergoing pituitary suppression in assisted reproduction
Long protocol (GnRHa until HCG) showed no clear difference in live birth and ongoing pregnancies per woman randomised compared with long protocol (extend GnRHa 12 days after HCG) (low certainty).
1 finding from 1 review
Clinical pregnancy rate · women undergoing pituitary suppression in assisted reproduction
Long protocol (GnRHa until HCG) showed no clear difference in clinical pregnancies per woman randomised compared with long protocol (extend GnRHa 12 days after HCG) (low certainty).
1 finding from 1 review
Participant‐reported improvement of hirsutism ‐ not measured · women with hirsutism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants who reported an adverse event · women with hirsutism
It is very uncertain whether flutamide 250 mg once to twice daily changes proportion of participants who reported an adverse event compared with metformin 1275 mg to 1700 mg per day (very low certainty).
1 finding from 1 review
Clinician's assessment of improvement of hirsutism Ferriman‐Gallwey score Scale from: 0 to 36 · women with hirsutism
1 finding from 1 review
Change in serum androgen levels · women with hirsutism
1 finding from 1 review
Change in BMI3 kg/m² · women with hirsutism
1 finding from 1 review
Improvement of other clinical signs of hyperandrogenism ‐ not measured · women with hirsutism
1 finding from 1 review
Fever clearance time · children with acute pyelonephritis
1 finding from 1 review
Renal parenchymal damage at 6 to 12 months: all included children with acute pyelonephritis DMSA scans · children with acute pyelonephritis
Oral showed no clear difference in renal parenchymal damage at 6 to 12 months: all included children… compared with IV followed by oral (11 days) therapy (moderate certainty).
1 finding from 1 review
Renal parenchymal damage at 6 to 12 months: children with renal parenchymal damage on initial DMSA · children with acute pyelonephritis
Oral showed no clear difference in renal parenchymal damage at 6 to 12 months: children with renal… compared with IV followed by oral (11 days) therapy (moderate certainty).
1 finding from 1 review